Index

Note: Page numbers of article titles are in boldface type.

A

Acarbose, 541, 543
Acetaminophen toxicity, transplantation for, 453–454
Acute cellular rejection
   in kidney transplantation, 494–495
   in liver transplantation, 479–480
Acute Kidney Injury Network staging system, 489–490
Acute rejection, of kidney allograft, 496–497
Acute tubular necrosis, in kidney transplantation, 492–493
Acyclovir, prophylactic, 594–595
Age factors
   in living donor, 601, 603
   in transplant recipient, 469–470
Alanine aminotransferase, in liver allograft dysfunction, 478
Albiglutide, 542–544
Albumin level, in MELD score, 451
Albuminuria, in kidney allograft dysfunction, 489
Alcohol abuse, 460, 481, 577
Alemtuzumab, 439, 512
ALERT (Lescol in Renal Transplantation) Trial, 526–527
Alkaline phosphatase, 478, 576
Allograft dysfunction
   in kidney transplantation, 487–503
      causes of, 488–489
      diagnosis of, 488–491
      early (up to 6 months), 491–496
      later, 496–499
      symptoms of, 488
   in liver transplantation, 477–486
      causes of, 478
      definition of, 478
      differential diagnosis of, 478–482
      monitoring of, 482
      recurrence of, 482
      treatment of, 483–484
Allopurinol, 510
Alogliptin, 542–543
Alpha-glucosidase inhibitors, 541, 543
Alport syndrome, 470
American Association for the Study of Liver Diseases guidelines, 453–454
American College of Cardiology, coronary artery disease guidelines of, 468–469
American Heart Association, coronary artery disease guidelines of, 468–469
Anemia, 510, 527
Angiography, for renal artery stenosis, 497
Angiotensin receptor blockers, 524
Angiotensin-converting enzyme inhibitors, 523–524
Animal studies, 440
Anogenital cancer, 554, 560
Anti lymphocyte globulin, history of, 441
Anti proliferative agents, 509–511, 538
Antibiotics, 513
drug interactions of, 509
prophylactic, after transplantation, 594–595
Antibody-mediated rejection, in kidney transplantation, 494–495, 497
Anticonvulsants, 510
Antifungal agents, 509, 513
Anti-glomerular basement membrane disease, 470
Antihypertensives, 513
Antimetabolites, 509–510
Antineutrophil cytoplasmic antibody vasculitis, 470
Antithymocyte antibodies, 512
Anxiety, 514
Art, Surgery and Transplantation, 439
Ascites, in MELD score, 451
Aspartate aminotransferase, in liver allograft dysfunction, 478
Aspergillosis, 593
Atorvastatin, 526
Autoimmune hepatitis, 454, 481
Avascular necrosis, 574, 581
Azathioprine, 509–510one disease and, 575
history of, 439, 441, 506
in pregnancy, 618–620
side effects of, 516

B
Banff criteria, 492–493
Basal cell carcinoma, 553–555
B-cell lymphomas, 555–556
Belatecept, 439, 511–512, 516
diabetes mellitus due to, 539
in pregnancy, 618
Beltzer, Folkert, 442
Beta blockers, 513, 524
Bile leaks, in liver transplantation, 479, 483
Biliary complications, after liver transplantation, 479
Biliary obstruction, after liver transplantation, 483–484
Bilirubin level, in MELD score, 451
Bilomas, after liver transplantation, 479
Biomarkers, bone, 576
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td>577, 572</td>
</tr>
<tr>
<td>bone, 577</td>
<td></td>
</tr>
<tr>
<td>of kidney allograft, 491, 497</td>
<td></td>
</tr>
<tr>
<td>Bisphosphonates, 580–581</td>
<td></td>
</tr>
<tr>
<td>BK virus nephropathy, 493, 593</td>
<td></td>
</tr>
<tr>
<td>Bladder, cancer of, 558–559</td>
<td></td>
</tr>
<tr>
<td>Bladder dysfunction, in kidney allograft, 494</td>
<td></td>
</tr>
<tr>
<td>Bone densitometry, 576</td>
<td></td>
</tr>
<tr>
<td>Bone loss. See Metabolic bone disease.</td>
<td></td>
</tr>
<tr>
<td>Borel, Jean, 439, 506</td>
<td></td>
</tr>
<tr>
<td>Bortezimib, 445</td>
<td></td>
</tr>
<tr>
<td>Breast cancer, 560</td>
<td></td>
</tr>
<tr>
<td>Breastfeeding, 622</td>
<td></td>
</tr>
<tr>
<td>Brescia, Michael, 438</td>
<td></td>
</tr>
</tbody>
</table>

C
Calcidiol, 580
Calcineurin, action of, 507
Calcineurin inhibitors
bone disease due to, 574
diabetes mellitus due to, 538–539
drug interactions with, 507, 509
in pregnancy, 618–619
mechanism of action of, 506–507, 509
nephrotoxicity of, 498–499, 507, 509
Calcitonin, 579–580
Calctirio, 580
Calcium, supplementation of, 577–578
Calcium channel blockers, 509, 513, 523–524
Calne, Roy, 439, 441
Canagliflozin, 542, 544
Cancer. See Malignancies.
Cannon, Jack, 439
Cardiac catheterization, 468–469
Cardiomyopathy, 468–469
Cardiovascular disease, 519–533
epidemiology of, 520–521
in immunosuppressive therapy, 515, 517
in kidney transplantation, 467–469
risk factors for, 521–529
Cardiovascular examination, 457–458
Carotid arteries, stenosis of, 469
Carrel, Alex, 436, 505
Casts, in kidney allograft dysfunction, 490
Cerebrovascular disease, 469
Cervical cancer, 560
Child-Turcotte-Pugh score, for liver transplantation decisions, 449–451
Cholangiocarcinoma, transplantation for, 456
Cholangitis, 593
Cholestasis, bone disease in, 572
Chronic allograft nephropathy, 498–499
Chronic kidney disease, transplantation for, 465–476
  evaluation for, 466–475
  kidney allocation system for, 465–466
  wait list for, 466
Chronic Kidney Disease Epidemiology Collaboration equation, 488–489
Cimino, James, 438
Cinacalcet, 580
Ciprofloxacin, 513
Cirrhosis, transplantation for, 454–455
Citalopram, 514
Claudication, 469
Clonidine, 524
Coagulopathy, in MELD score, 451
Cognitive function, after transplantation, 614
Cold remedies, 514
Collaborative Transplant Study, 522
Colorectal cancer, 554, 559
Computed tomography
  for bone density, 576–577
  for kidney allograft dysfunction, 490–491, 494
Congestive heart failure, 521
Constant region (Fc), of antibodies, 512
Contraception, after transplantation, 617
Contraindications, to kidney transplantation, 466
Conversion immunosuppression, 515
Coronary artery disease, 457–458, 468–469
Corticosteroids, 511
  avoidance of, 579
  bone disease due to, 573–574, 579
  diabetes mellitus due to, 538
  history of, 439
  side effects of, 516, 527–529
Costimulation blockade, 511–512
C-reactive protein, 527
Creatinine level, in kidney transplantation, 488, 496
C-terminal telopeptide of type 1 collagen, 576
Cyclosporine
  bone disease due to, 574
  diabetes mellitus due to, 538–539
  history of, 439, 506
  in pregnancy, 618–620
  mechanism of action of, 507–509
  side effects of, 495–496, 516, 527–529
Cystitis, 592
Cytomegalovirus infections, 480, 483–484, 592–594
Cytotoxic T-lymphocyte 4, 511–512
Dapagliflozin, 542
Decompenation, MELD score in, 454
Dehydroepiandrosterone, 579
Delayed allograft function, in kidney transplantation, 492–493
Denosumab, 580–581
Dense deposit disease, 470
Depression, 514
Desensitization, 473
Detemir, 541
Diabetes mellitus, 535–550
  after transplantation, 523–524
  bone disease in, 571
  groups of, 537
  in living donors, 604
  new-onset after transplant (NODAT), 515, 523–524, 535–550
    bone disease in, 575
    definition of, 537–538
    diagnosis of, 537–538
    immunosuppressive drugs and, 538–539
    risk factors for, 538
    treatment of, 539–545
Dipeptidyl peptidase-4 inhibitors, 543–544
Domino transplantation, liver, 443
Donation Service Areas, 452
Donors
  for transplantation, 442–444
  infections in, 590
  living, 442–444, 599–613
Doppler studies, of carotid arteries, 469
Drug(s)
  bone disease due to, 571
  hepatotoxicity of, 482–483
Drug abuse, 460, 472
Dual energy x-ray absorptiometry (DEXA), 576–577
Dulaglutide, 543–544
Dyslipidemia, 514, 524–526

E
Echocardiography, 457–458, 469
Elion, Gertrude, 506
Empagliflozin, 542, 544
Employment, after transplantation, 615
Encephalopathy, in MELD score, 451
Entecavir, prophylactic, 594–595
Epstein-Barr virus, 555–556
Escitalopram, 514
Estimated glomerular filtrate rate, in kidney allograft monitoring, 488–490
Estimated Post-Transplant Survival Score, 466
Estradiol, replacement of, 579
European Renal Best Practice Advisory Board guidelines, 556

Everolimus, 510–511
  - bone disease due to, 575
  - in pregnancy, 618–619
  - nephrotoxicity of, 499
  - side effects of, 516, 527–529

Exenatide, 542–544
  - “Extended criteria” donors, 442–443

F

Familial amyloidotic polyneuropathy, 454

Fenofovir, prophylactic, 595

Fertility, after transplantation, 617–624

Final Rule, 438

Focal segmental glomerulosclerosis, 470, 498

Fractures. See Metabolic bone disease.

Functional recovery, after transplantation, 614–615

G

Genital cancer, 554, 560

Glargine, 541

Glinides, 541

Glipizide, 541, 544–545

Glomerulonephritis
  - in allograft dysfunction, 497–498
  - membranoproliferative, 470
  - recurrent, 469

Glucagon-like peptide 1 receptor agonists, 543–544

Glucocorticoids. See Corticosteroids.

Glyburide, 541

H

Head and neck cancer, 554, 556

Health-related quality of life, after transplantation, 614–617

HELLP syndrome, 621

Hematologic disorders, in antimetabolite therapy, 510

Hematoma, in allograft dysfunction, 493–494

Hematuria, in kidney allograft dysfunction, 490

Hemolytic uremic syndrome
  - atypical, 470
  - in allograft dysfunction, 495

Hepatic artery, thrombosis of, 478–479, 483–484

Hepatic osteodystrophy, 572

Hepatic vein, thrombosis of, 479

Hepatitis, autoimmune, 454, 481

Hepatitis A, evaluation for, 459

Hepatitis B, 454
  - evaluation for, 459, 472
  - in liver transplantation, 481, 483–484
prevention of, 595

Hepatitis C
  evaluation for, 471–472
  in liver transplantation, 480, 483–484

Hepatitis E, 482–483

Hepatocellular carcinoma, 559
  after liver transplantation, 483–484
  recurrence of, 481
  risk factors for, 554
  screening for, 459
  transplantation for, 455–456

Hepatopulmonary syndrome, 454–455, 457–458

Herbal medications, 510, 514

Herpes simplex virus, 593

Herpesvirus-6, 593

Histocompatibility, 473

Histomorphometry, 577

Historical perspective, 435–448
  animal studies, 440
  earliest attempts, 435–436
  government approval, 441
  legal aspects, 438–439
  milestones in, 437–439
  moratorium, 440–441
  nineteenth century, 436
  organ allocation, 442–443, 450–452
  organ supply and demand disparity, 441–442
  pioneers, 439
  tacrolimus introduction, 441
  transplant center, 444–445
  twentieth century, 436–438

Hitchings, George, 506

Hodgkin lymphoma, 555–556

Holman, Emile, 505

Homocysteine, 527

Hormone replacement therapy, 579

Human herpesvirus-6, 555

Human immunodeficiency infection
  bone disease in, 571
  evaluation for, 459, 471

Human leukocyte antigens, 473, 493

Human papillomavirus, 555, 560

Hydralazine, 524

Hydronephrosis
  in allograft dysfunction, 493–494
  in kidney transplantation, 491

Hydroureter, in allograft dysfunction, 493–494

Hyperacute rejection, of kidney allograft, 492

Hyperlipidemia, 514, 524–526

Hyperoxaluria, primary, 454

Hyperparathyroidism, 571–573, 575
Hypertension, 521–523, 604
Hypertriglyceridemia, in immunosuppressive therapy, 511
Hypogonadism, 574
Hypophosphatemia, 573

I
Ibandronate, 580
Immunoglobulin A nephropathy, 470
Immunosuppressive therapy, 505–518. See also individual drugs.
adjunct agents with, 513–514
bone disease due to, 573–575
cardiovascular disease and, 527–529
complications of, 515–517
diabetes mellitus due to, 538–539
future of, 445
history of, 438–439, 441, 505–506
infections in, 590
malignancies due to, 553
mechanism of action of, 506–507, 509
pharmacokinetics of, 513
phases of, 507–509
teratogenic risks of, 618
within immune system, 507–512
INDIGO (Kidney Disease Improving Global Outcome) guidelines, 522, 575
Infections
evaluation for, 459, 471
posttransplant, 479, 587–598
active, 589–590
after six months, 593–594
between one and six months, 592–593
diagnostic tools for, 588–589
in first month, 591–592
in pregnancy, 618
latent, 589–590
microbiology of, 588
prevention of, 594–596
principles of, 588–589
risk factors for, 589–590
symptoms of, 588
timeline of, 590–591
treatment of, 589
variety of, 588
Infliximab, 512
Insulin, 536–537, 539–541, 544
International Consensus Guideline, for NODAT, 523–524, 537
Israel Penn International Transplant Tumor Registry, 459

J
Jaboulay, Mathieu, 505
K

Kaposi sarcoma, 555
Kidney, cancer of, 558–559
Kidney allocation system, 465–466
Kidney Disease Improving Global Outcome (INDIGO) guidelines, 522, 575
Kidney Disease Outcomes Quality Initiative, 575
Kidney Donor Profile Index, 466
Kidney transplantation
  cardiovascular risk in, 519–533
  diabetes mellitus care after, 535–550
  for advanced chronic kidney disease, 465–476
  historical perspective of, 435–448
  immunosuppressive therapy for, 505–518
  infections after, 587–598
  living donors for, 599–611
  malignancies after, 551–567
  metabolic bone disease after, 569–586
  outcomes of, 613–629

L

Labor and delivery, in transplant patients, 621
Lescol in Renal Transplantation (ALERT) Trial, 526–527
Lifestyle changes
  for bone disease, 577
  for diabetes mellitus, 539
Linagliptin, 543
Liraglutide, 542–544
Liver failure, acute, transplantation for, 453–454
Liver function tests, in allograft dysfunction, 478
Liver transplantation
  allograft dysfunction in, 477–503
  cardiovascular risk, 519–533
  diabetes mellitus care after, 535–550
  historical perspective of, 435–448
  indications for, 444–467
  infections after, 587–598
  living donors for, 599–611
  malignancies after, 551–567
  metabolic bone disease after, 569–586
  outcomes of, 613–629
Living donors, 442–444, 599–611
  indications and contraindications for, 601–608
  postoperative care of, 605
  preparation of, 601
  psychosocial outcomes in, 608
  risks for, 605–608
Lung cancer, 554, 556–558
Lupus nephritis, 470
Lymphocele, in allograft dysfunction, 493–494
Lymphomas, 555–556
M

Macrolides, 513
Magnetic resonance imaging, for kidney allograft dysfunction, 490–491
Male transplant recipients, parenthood in, 624
Malignancies, 551–567
  in immunosuppressive therapy, 517
  incidence of, 552–553
  mortality in, 552–553
  posttransplant lymphoproliferative disorder, 555–556
  risk factors for, 553
  skin, 553–555
  solid organ tumors, 556–560
  surveillance for, 560–561
Mammalian target of rapamycin inhibitors
  diabetes mellitus due to, 539
  side effects of, 527–529
Mammalian target of rapamycin kinase, action of, 507, 510–511
Medawar, Peter, 438
MELD (Model for End-Stage Liver Disease), 444, 449–464
  benefits of, 451
  exceptions for, 452
  for evaluation, 456–460
  for indications and, 452–456
  historical perspective of, 450–452
Membranoproliferative glomerulonephritis, 470
Membranous nephropathy, 470, 498
Mental health, drugs for, 514
6-Mercaptopurine, 509–510
MESSAGE (MELD Exception Study Group and Conference), 444
Metabolic bone disease, post-transplant, 569–586
  biochemistry of, 575–576
  causes of, 570–575
  epidemiology of, 570
  monitoring of, 575–577
  pathophysiology of, 575–576
  treatment of, 577–581
Metabolic syndrome, 527
Metastasis, from hepatocellular carcinoma, 456
Metformin, 540–542, 544–545
Methylprednisolone pulse therapy, 581
Microangiopathy, thrombotic, in kidney allograft, 495
Miglitol, 541, 543
Milan Criteria, for hepatocellular carcinoma, 455–456
Minoxidil, 524
Model for End-Stage Liver Disease. See MELD (Model for End Stage Liver Disease).
Modification of Diet in Renal Disease study, 488
Monoclonal anybodies, 439, 512
Moore, Francis, 440
Murray, Joseph, 436, 439, 506, 600
Mycophenolates, 509–510
bone disease and, 575
  history of, 439
   in pregnancy, 618–619
   side effects of, 516
Myocardial infarction, 468–469, 521

N
Natetlinide, 543
National Institutes of Health, transplantation approval by, 441
Nephritis, lupus, 470
Nephropathy
  BK virus, 493
   membranous, 470
Nephrotoxicity, of drugs, 507, 509, 515
NODAT. See Diabetes mellitus, new-onset after transplant.
Nucleotide synthesis, in calcineurin action, 507
Nutrition, evaluation of, 459–460
Nystatin, prophylactic, 594–595

O
Obesity, 472, 527
   in living donors, 604
   screening for, 460
Opportunistic infections, 592–594
OPTN final rule, 444
Organ allocation policy, historical perspective of, 450–452
Organ Procurement and Transplantation Network, 438, 601
Organ Procurement Organization, 452
Osteoblasts, corticosteroid effects on, 573–574
Osteoclasts, corticosteroid effects on, 574
Osteocytes, corticosteroid effects on, 574
Osteodystrophy
   hepatic, 572
   renal, 571–572
Osteonecrosis, 574, 581
Osteoporosis. See Metabolic bone disease.
Outcomes, of solid organ transplantation, 613–629
   functional recovery, 614–615
   health-related quality of life, 614–617
   pregnancy, 617–624
Oxalosis, 470

P
Pancreas, transplantation of, with kidney transplantation, 473–475, 573
Parathyroid dysfunction, 571–573, 575
Patient education
   for diabetes mellitus, 537
   for kidney transplantation, 467
PELD (Pediatric End-Stage Liver Disease) system, 444
Penile cancer, 560
Peripheral vascular disease, 469
Physical function, after transplantation, 614–615
Pioglitazone, 543
*Pneumocystis jiroveci*, 594
Pneumonia
  - after liver transplantation, 479
  - in immunosuppressive therapy, 511
Polyclonal antibodies, 512
Polycystic kidney disease, 469
Polyneuropathy, familial amyloidotic, 454
Portopulmonary hypertension, 454–455, 457–458
Posttransplant lymphoproliferative disorder, 554–556
Pravastatin, 514, 526
Prednisone
  - history of, 441
  - in pregnancy, 618–619
Pregnancy, after transplantation, 617–624
Preventive health care, 514
Primary biliary cirrhosis, bone disease in, 572
Proglitazone, 541
Pro-oncogenic viruses, 553
Prostate cancer, 558–559
Proteinuria, in kidney allograft monitoring, 488–490
Pulmonary examination, 457–458
Pulmonary function tests, 472
Pulmonary hypertension, 469
*The Puzzle People*, 439–440

R
Radionuclide imaging, for kidney allograft dysfunction, 490–491
Redundancy, of immune system, 506–507
Rejection
  - antibody-mediated, 497
  - in pregnancy, 621
  - of kidney allograft, 492
  - of liver allograft, 479–480, 483
Renal artery
  - stenosis of, 497
  - thrombosis of, 491–492
Renal cell carcinoma, 558–559
Renal osteodystrophy, 571–572
Renal transplantation. See Kidney transplantation.
Renal vein, thrombosis of, 492
Repaglinide, 541, 543
Repeat transplantation, kidney, 473
Reproductive function, after transplantation, 617–624
Return to work, after transplantation, 615
Rituximab, 512
Rosiglitazone, 541, 543
Rosuvastatin, 514, 526

S
Saxagliptin, 542–543
Scientific Registry for Transplant Recipients, 442–444
Scribner, Belding, 438
Sensitized persons, 473
Sepsis, after liver transplantation, 479, 483
Sexuality, after transplantation, 617–624
Share 35 policy, 444, 452
Simvastatin, 526
Sirolimus, 510–511
  bone disease and, 575
  diabetes mellitus due to, 539
  in pregnancy, 618–619
  nephrotoxicity of, 499
  side effects of, 516, 527–529
Sitagliptin, 541, 543
Skin cancer, 553–555
Slush technique, 442
Smoking, 472, 526–527, 577
Sodium-glucose cotransporter 3 inhibitors, 544
Solid organ transplantation. See also Kidney transplantation; Liver transplantation.
  cardiovascular risk in, 519–533
  diabetes mellitus care after, 535–550
  historical perspective of, 435–448
  immunosuppressive therapy for, 505–518
  infections after, 587–598
  living donors for, 599–611
  malignancies after, 551–567
  outcomes of, 613–629
Southard, James, 442
Squamous cell carcinoma, 553–555
Starzl, Thomas, 439–441, 450
Statins, 514, 525–526
Stenosis, of renal artery, 497
Stents, urinary, for allograft dysfunction, 493
Stress testing, 468–469
Sulaglutide, 542
Sulfomethoxazole-trimethoprim, drug interactions of, 496
Sulfonylureas, 541–543
Surveillance, for malignancies, 560–561
Syphilis, evaluation for, 459, 471
Systemic lupus erythematosus, bone disease in, 571

T
Tacrolimus
  bone disease due to, 574
Tacrolimus (continued)
  diabetes mellitus due to, 538–539
  history of, 439, 441–442
  in pregnancy, 618–620
  mechanism of action of, 507–509
  side effects of, 495–496, 516, 527–529
T-cell lymphomas, 555–556
Teriparatide, 580
Testosterone therapy, 579
Tetracyclin double-labeled transiliac crest bone biopsy, 577
Thiazide diuretics, 513, 524
Thiazolidinediones, 541, 543
Thrombocytopenia, in immunosuppressive therapy, 511
Thrombophilia, 473
Thrombosis
  of hepatic artery, 478–479, 483–484
  of hepatic vein, 479
  of portal vein, 479
  of renal artery, 491–492
  of renal vein, 492
Thrombotic microangiopathy, in kidney allograft, 495
Thyroid cancer, 556
Tissue culture, replacement organs from, 445
Tobacco use, 472, 526–527, 577
Transient ischemic attacks, 469
Transplant centers, 444–445
Transplant renal artery stenosis, 497
Transplantation. See Kidney transplantation; Liver transplantation.
  offspring produced after, 624
  pancreas, with kidney transplantation, 474–475, 573
Transplantation Act of 1987, 450
Transthyretin gene mutations, 454
Trimethoprim-sulfamethoxazole, prophylactic, 594–595
Tuberculosis, evaluation for, 459, 471
Tumors. See Malignancies.

U
Ullman, Emerich, 436, 505
Ultrasonography
  for cancer, 558
  for kidney allograft dysfunction, 490–491, 494
  for renal artery stenosis, 497
Unagliptin, 542
Uniform Anatomic Gift Act of 1968, 438
United Network for Organ sharing, 438, 450–455, 519
United States Renal Data System, 520–521, 523–524
Ureter, stenosis of, in allograft dysfunction, 493–494
Ureterostomy, for allograft dysfunction, 493
Urinalysis, for kidney allograft dysfunction, 489–490
Urinary leaks, for kidney allograft dysfunction, 493
Urinary obstruction, for kidney allograft dysfunction, 493
Urinary tests, for kidney allograft dysfunction, 489–490
Urinary tract infections, 592
Urinoma, in allograft dysfunction, 493–494
Urolithiasis, in kidney allograft, 494

V
Vaccinations, 514, 595–596
  before kidney transplantation, 471
  before liver transplantation, 459
Vaginal cancer, 560
Valacyclovir, prophylactic, 594–595
Valgancyclovir, prophylactic, 594–595
Variable region (Fab), of antibodies, 512
Varicella zoster virus, 593
Vascular complications, after liver transplantation, 479
Vasculitis, antineutrophil cytoplasmic antibody, 470
Venography, for renal vein thrombosis, 492
Venous outflow obstruction, after liver transplantation, 483–484
Ventricular hypertrophy, left, 521–523
Viruses, pro-oncogenic, 553
Vitamin D, supplementation of, 577–580
Vulvar cancer, 560

W
Wait lists
  for chronic kidney disease, 466
  for liver transplantation, 449–450
Welch, C. Stuart, 439

Y
Yuronoy, Yu Yu, 436